Vascular endothelial growth factor polymorphisms: Role in response and toxicity of tyrosine kinase inhibitors

Current Oncology Reports

Volumn 12, Issue 2, 2010, Pages 102-108

  Vaziri, Susan A J ^a   Kim, Jenny ^a   Ganapathi, Mahrukh K ^a   Ganapathi, Ram ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Hypertension; Outcome; Toxicity; Tyrosine kinase inhibitors; VEGF polymorphism

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CYCLOPHOSPHAMIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENETIC VARIABILITY; GENOTYPE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY METASTASIS; MONOTHERAPY; MUCOSAL BLEEDING; NEOPLASM; NONHUMAN; OVARY CANCER; OVARY METASTASIS; PHARMACOGENETICS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR BLEEDING; TUMOR VASCULARIZATION; WOUND COMPLICATION;

ANIMALS; HUMANS; HYPERTENSION; NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77952242619     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0085-4     Document Type: Review

References (54)

1. J Folkman 2006 Angiogenesis. Annu Rev Med 57 1 8 10.1146/annurev.med.57. 121304.131306 1:CAS:528:DC%2BD28Xis1Cksrg%3D (Pubitemid 43261975)
2. P Bhargava 2009 VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297 R1 R5 1:CAS:528:DC%2BD1MXovVKitbY%3D 19439616
3. DePrimo SE, Bello CL, Smeraglia J, et al.: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32-43. This informative article discusses circulating biomarkers in mRCC patients treated with sunitinib.
4. Ebos JML, Lee CR, Christensen JG, et al.: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. PNAS 2007, 104:17069-17074. This article discusses possible tumor-independence of circulating proangiogenic factors during treatment with sunitinib.
5. BI Rini 2008 M, Rosenberg JE, et al.: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 3743 3748 10.1200/JCO.2007.15.5416 1:CAS:528:DC%2BD1cXhtVGjs73L 18669461
6. DR Feldman MS Baum MS Ginsberg, et al. 2009 Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 1432 1439 10.1200/JCO.2008.19.0108 1:CAS:528:DC%2BD1MXksF2hs7w%3D 19224847
7. DC Sane L Anton B Brosnihan 2004 Angiogenic growth factors and hypertension Angiogenesis 7 193 201 10.1007/s10456-004-2699-3 1:CAS:528:DC%2BD2MXht1KjsbY%3D 15609074
8. JD Hood CJ Meininger M Ziche, et al. 1998 VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol 274 H1054 H1058 1:CAS:528:DyaK1cXitVSjs7c%3D 9530221
9. JR Horowitz A Rivard R van der Zee, et al. 1997 Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension Arterioscler Thromb Vasc Biol 17 2793 2800 1:CAS:528: DyaK1cXisV2jtg%3D%3D 9409257
10. G Ciuffetti G Schillaci S Innocente, et al. 2003 Capillary rarefaction and abnormal cardiovascular reactivity in hypertension J Hypertens 21 2297 2303 10.1097/00004872-200312000-00018 1:CAS:528:DC%2BD3sXpsVGhs7c%3D 14654750 (Pubitemid 38293569)
11. JC Yang L Haworth RM Sherry, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 1:CAS:528: DC%2BD3sXms1Klu7w%3D 12890841 (Pubitemid 36910021)
12. ML Maitland K Moshier J Imperial, et al. 2035 Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway J Clin Oncol 2006 24
13. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
14. FJ Giordano HP Gerber SP Williams, et al. 2001 A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function PNAS 98 5780 5785 10.1073/pnas.091415198 1:CAS:528:DC%2BD3MXjs1Wntr4%3D 11331753 (Pubitemid 32435719)
15. Chu TF, Rupnick MA, Kerkela R, et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet Oncol 2007, 370:2011-2019. This article reviews TKI-associated cardiotoxicity.
16. O Rixe RM Bukowski 2007 Dror Michaelson M, et al.: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 975 984 10.1016/S1470-2045(07)70285-1 17959415 (Pubitemid 47629888)
17. V Eremina M Sood J Haigh, et al. 2003 Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 111 707 716 1:CAS:528:DC%2BD3sXhvFenurs%3D 12618525
18. BF Schrijvers A Flyvbjerg AS DeVrise 2004 The role of vascular endothelial growth factor (VEGF) in renal pathophysiology Kidney Int 65 2003 2017 10.1111/j.1523-1755.2004.00621.x 1:CAS:528:DC%2BD2cXltFKgs7c%3D 15149314 (Pubitemid 38669987)
19. V Eremina JA Jefferson J Kowalewska, et al. 2008 VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 1129 1136 10.1056/ NEJMoa0707330 1:CAS:528:DC%2BD1cXjt1ahs7o%3D 18337603 (Pubitemid 351398487)
20. RK Barakat N Singh R Lal, et al. 2007 Interstitial nephritis secondary to bevacizumab treatment in metastatic meiomyosarcoma Ann Pharmacother 41 707 710 10.1345/aph.1H635 1:CAS:528:DC%2BD2sXltlOns78%3D 17374619 (Pubitemid 46625498)
21. C Frankie C Leachier J Medina, et al. 2007 Renal thrombosis microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma Lancet Oncol 8 177 178 10.1016/S1470-2045(07)70037-2 (Pubitemid 46158384)
22. D Roncone A Sattskar T Nadasdy, et al. 2007 Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma Nat Clin Pract 3 287 293 10.1038/ncpneph0476 (Pubitemid 46674523)
23. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
24. Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191
25. McDermott DF, Soman JA, Gonzalez R, et al.: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J Clin Oncol 2008, 26:2178-2185.
26. Y Kawai S Sakano Y Korenaga, et al. 2007 Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas Eur Urol 52 1147 1155 10.1016/j.eururo.2007.01.073 1:CAS:528:DC%2BD2sXht1WgurfF 17287073 (Pubitemid 47332024)
27. DH Kim NY Lee MH Lee, et al. 2007 Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients Br J Haematol 140 71 79 17983459
28. Schneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in trial of paclitaxel compared with paclitaxel compared with pacitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 20:4672-4678. This publication provides important information on VEGF SNPs that are associated with outcome and toxicity in patients treated with bevacizumab.
29. PJ Hsiao MY Lu FY Chiang, et al. 2007 Vascular endothelial growth factor gene polymorphisms in thyroid cancer J Endocrinol 195 265 270 10.1677/JOE-07-0395 1:CAS:528:DC%2BD2sXhtlGms73L 17951537 (Pubitemid 350143106)
30. EJ Jacobs HS Feigelson EB Bain, et al. 2006 Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort Breast Cancer Res 8 R22 10.1186/bcr1400 16613616 (Pubitemid 44377909)
31. R Zhai G Liu K Asomaning, et al. 2008 Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk Carcinogenesis 29 2330 2334 10.1093/carcin/bgn210 1:CAS:528:DC%2BD1cXhsVOgsLfN 18780893
32. T Cacev B Loncar S Seiwerth, et al. 2008 Vascular endothelial growth factor polymorphisms -1154G/A and -460C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer DNA Cell Biol 27 569 574 10.1089/dna.2008.0756 1:CAS:528:DC%2BD1cXhtFKhurjE 18613756
33. RS Heist R Zhai G Lui, et al. 2008 VEGF polymorphisms and survival in early-stage non-small-cell lung cancer J Clin Oncol 26 856 862 10.1200/JCO.2007.13.5947 1:CAS:528:DC%2BD1cXjtFelsb8%3D 18281657 (Pubitemid 351398076)
34. C Ricketts MP Zeegers J Lubinski, et al. 2009 Analysis of germline variants in CDH1, IGFBBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma PloS One 4 e6037 10.1371/journal.pone.0006037 19551141
35. MP Smerdel M Waldstrom I Brandslund, et al. 2009 Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer Int J Gynecol Cancer 19 578 584 19509553
36. M Garcia-Closas N Malats FX Real, et al. 2007 Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk PLoS Genet 3 e29 10.1371/journal.pgen.0030029 17319747
37. SJ Bae DH Ahn SP Hong, et al. 2008 Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patient with stomach cancer Yonsei Med J 29 783 791 10.3349/ymj.2008.49.5.783
38. AJ Churchill JG Carter C Ramsden, et al. 2008 VEGF Polymorphisms are associated with severity of diabetic retinopathy Invest Ophtalmol Vis Sci 49 3611 3616 10.1167/iovs.07-1383
39. K Nakanishi C Watanabe 2009 Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes Clin Chim Acta 402 171 175 10.1016/j.cca.2009.01.004 1:CAS:528:DC%2BD1MXisFaht7c%3D 19263526
40. WB Breunis MH Biezeveld J Geissler, et al. 2009 Vascular endothelial growth factor gene haplotypes in Kawasaki disease Arthritis Rheum 54 1588 1594 10.1002/art.21811
41. Q Yuan X Zuo J Jia 2009 Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among northern Chinese Han Neurosci Lett 457 133 136 10.1016/j.neulet.2009.03.078 1:CAS:528:DC%2BD1MXls12jtbg%3D 19429179
42. C Salvarani L Boiardi B Casali, et al. 2004 Vascular endothelial growth factor gene polymorphisms in Behcet's disease J Rheumatol 31 1785 1789 1:CAS:528:DC%2BD2cXosVKls70%3D 15338501
43. G Galazioz D Papazoglou P Tsikouras, et al. 2009 Vascular endothelial growth factor gene polymorphisms and pregnancy J Matern Fetal Neonatal Med 22 371 378 10.1080/14767050802645035
44. LM Lin L Wan YY Tsai, et al. 2008 Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration Am J Opthalmol 145 1045 1051 10.1016/j.ajo.2008.01.027 1:CAS:528:DC%2BD1cXmt1Ontrg%3D
45. C Butt S Lim C Greenwood, et al. 2007 VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis BMC Musculoskelet Disord 8 1 10.1186/1471-2474-8-1 17204151 (Pubitemid 46169616)
46. B Rueda MA Lopez-Nevot MJ Lopez-Diaz, et al. 2005 A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis J Rheumatol 32 1737 1743 1:CAS:528:DC%2BD2MXhtFSktb7O 16142870
47. K Doi E Noiri A Nakao, et al. 2006 Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males J Am Soc Nephrol 17 823 830 10.1681/ASN.2005010094 1:CAS:528:DC%2BD28XislCqsLc%3D 16421229
48. G Pages J Puyssegur 2005 Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors Cardiovascular Res 65 564 573 10.1016/j.cardiores.2004.09.032 1:CAS:528:DC%2BD2MXmsVKmtA%3D%3D (Pubitemid 40138977)
49. J Pander H Gelderblom HJ Guchelaar 2007 Pharmacogenetics of EGFR and VEGF inhibition Drug Discov Today 12 1054 1060 10.1016/j.drudis.2007.10.016 1:CAS:528:DC%2BD2sXhsVSmurnL 18061885 (Pubitemid 350180563)
50. W Renner S Kotschan C Hoffmann, et al. 2000 A common 936 C/T Mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels J Vasc Res 37 443 448 10.1159/000054076 1:CAS:528:DC%2BD3MXoslGmsQ%3D%3D 11146397 (Pubitemid 32037619)
51. Bastide A, Karaa K, Bornes S, et al.: An upstream open reading frame with in an IRES controls expression of specific VEGF-A isoform. Nucleic Acids Res 2008, 36:2434-2445. This article identifies a region in the 5′UTR of VEGF (IRESB) that is critical in the expression of a VEGF isoform. The -634G>C SNP occurs in this region. This paper highlights the complex level of regulation of VEGF expression at the transcription and translation levels. (Pubitemid 351567014)
52. CS Facemire 2009 Nixon, AB, Griffiths R, et al.: Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression Hypertension 54 652 658 10.1161/HYPERTENSIONAHA.109.129973 1:CAS:528:DC%2BD1MXpslektL4%3D 19652084
53. JJ Kim SA Vaziri BI Elson, et al. 2009 VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695
54. AM Schultheis G Lurje KE Rhodes, et al. 2008 Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab Clin Can Res 14 7554 7563 10.1158/1078-0432.CCR-08-0351 1:CAS:528:DC%2BD1cXhtlylur3K